Ocular Therapeutix disclosed Phase 3 results showing its investigational drug Axpaxli maintained vision with fewer injections versus a low-dose Eylea comparator, meeting the trial’s primary endpoint for durability. The company reported that 74% and 66% of Axpaxli-treated patients were treatment-free at nine months and one year, respectively, versus 56% and 44% for low‑dose Eylea. Investors reacted with guarded enthusiasm after the initial release: while the statistical superiority on the primary endpoint strengthens Axpaxli’s clinical case, analysts flagged the smaller-than-expected durability gap versus an active control as a potential constraint on commercial uptake in a market already served by established anti‑VEGF agents. Ocular will need to frame real-world dosing benefits and payer economics to convince retina specialists to adopt a new standard of care. Regeneron and Bayer’s Eylea remains a high bar; Axpaxli’s path will hinge on longer-term head-to-head data, safety profile, and real-world durability that translate to fewer clinic visits and injection costs for patients and health systems.